2025 · 2nd Quarter (Apr 1 - June 30)
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Literal source text
Legislative issues related to access to pharmaceuticals; Rebates in Medicaid and for dual-eligibles; Medicaid coverage issues; 340B Drug Program; Medicare Part B and D prescription drug reimbursement. Pharmacy Benefit Management Reform in Medicare Part D, including provisions found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21.
Literal federal measure citations: H.R. 1
Monitor implementation of the 340B Prescription Drug Discount Program and implementation of the Inflation Reduction Act of 2022 (P.L. No: 117-169). Issues regarding FDA user fee programs. Pharmacy Benefit Management Reform. Public health issues impacting patient access to treatments.
Issues related to trade enforcement and protection. Issues related to TRIPS waivers (Trade-Related Aspects of Intellectual Property Rights).
Issues related to the FY26 National Defense Authorization Act.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
